{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:39:19Z","timestamp":1787654359416,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Research Collaboration"},{"name":"Universit\u00e4ts-Herzzentrum Freiburg - Bad Krozingen"},{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Lipoprotein(a) [Lp(a)] is an independent, genetically determined, and causal risk factor for cardiovascular disease. Laboratory data have suggested an interaction of Lp(a) with platelet function, potentially caused by its interaction with platelet receptors. So far, the potential association of Lp(a) with platelet activation and reactivity has not been proven in larger clinical cohorts. This study analyzed intrinsic platelet reactivity before loading with clopidogrel 600\u00a0mg and on-treatment platelet reactivity tested 24\u00a0h following loading in patients undergoing elective coronary angiography. Platelet reactivity was tested by optical aggregometry following stimulation with collagen or adenosine diphosphate as well as by flow cytometry. Lp(a) levels were directly measured in all patients from fresh samples. The present analysis included 1912 patients. Lp(a) levels ranged between 0 and 332\u00a0mg\/dl. There was a significant association of rising levels of Lp(a) with a higher prevalence of a history of ischemic heart disease (p\u2009&lt;\u20090.001) and more extensive coronary artery disease (p\u2009=\u20090.001). Results for intrinsic (p\u2009=\u20090.80) and on-clopidogrel platelet reactivity (p\u2009=\u20090.81) did not differ between quartiles of Lp(a) levels. Flow cytometry analyses of expression of different platelet surface proteins (CD41, CD62P or PAC-1) confirmed these findings. Correlation analyses of levels of Lp(a) with any of the tested platelet activation markers did not show any correlation. The present data do not support the hypothesis of an interaction of Lp(a) with platelet reactivity.<\/jats:p>","DOI":"10.1007\/s11239-021-02515-2","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T04:02:31Z","timestamp":1625198551000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6431-519X","authenticated-orcid":false,"given":"Alexander","family":"Kille","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"N\u00fchrenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Valina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Leibundgut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz-Josef","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willibald","family":"Hochholzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"issue":"22","key":"2515_CR1","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","volume":"301","author":"PR Kamstrup","year":"2009","unstructured":"Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301(22):2331\u20132339. https:\/\/doi.org\/10.1001\/jama.2009.801","journal-title":"JAMA"},{"issue":"23","key":"2515_CR2","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG et al (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31(23):2844\u20132853. https:\/\/doi.org\/10.1093\/eurheartj\/ehq386","journal-title":"Eur Heart J"},{"issue":"11","key":"2515_CR3","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1194\/jlr.R071233","volume":"57","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG, Langsted A (2016) Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res 57(11):1953\u20131975. https:\/\/doi.org\/10.1194\/jlr.R071233","journal-title":"J Lipid Res"},{"issue":"7","key":"2515_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","volume":"3","author":"S Burgess","year":"2018","unstructured":"Burgess S et al (2018) Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis. JAMA Cardiol 3(7):619\u2013627. https:\/\/doi.org\/10.1001\/jamacardio.2018.1470","journal-title":"JAMA Cardiol"},{"issue":"6","key":"2515_CR5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jacl.2014.08.003","volume":"8","author":"JP McConnell","year":"2014","unstructured":"McConnell JP, Guadagno PA, Dayspring TD, Hoefner DM, Thiselton DL, Warnick GR, Harris WS (2014) Lipoprotein(a) mass: a massively misunderstood metric. J Clin Lipidol 8(6):550\u2013553. https:\/\/doi.org\/10.1016\/j.jacl.2014.08.003","journal-title":"J Clin Lipidol"},{"issue":"11","key":"2515_CR6","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1161\/atvbaha.116.308011","volume":"36","author":"S Varvel","year":"2016","unstructured":"Varvel S, McConnell JP, Tsimikas S (2016) Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. Arterioscler Thromb Vasc Biol 36(11):2239\u20132245. https:\/\/doi.org\/10.1161\/atvbaha.116.308011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2515_CR7","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S et al (2020) Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med 382(3):244\u2013255. https:\/\/doi.org\/10.1056\/NEJMoa1905239","journal-title":"N Engl J Med"},{"issue":"10002","key":"2515_CR8","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/s0140-6736(15)61252-1","volume":"386","author":"S Tsimikas","year":"2015","unstructured":"Tsimikas S et al (2015) Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386(10002):1472\u20131483. https:\/\/doi.org\/10.1016\/s0140-6736(15)61252-1","journal-title":"Lancet"},{"issue":"8","key":"2515_CR9","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","volume":"60","author":"A Helgadottir","year":"2012","unstructured":"Helgadottir A et al (2012) Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol 60(8):722\u2013729. https:\/\/doi.org\/10.1016\/j.jacc.2012.01.078","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2515_CR10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/09537109876852","volume":"9","author":"DE Barre","year":"1998","unstructured":"Barre DE (1998) Lipoprotein (a) reduces platelet aggregation via apo(a)-mediated decreases in thromboxane A(2)production. Platelets 9(2):93\u201396. https:\/\/doi.org\/10.1080\/09537109876852","journal-title":"Platelets"},{"issue":"5\u20136","key":"2515_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.thromres.2004.01.002","volume":"112","author":"DE Barre","year":"2003","unstructured":"Barre DE (2003) Apolipoprotein (a) mediates the lipoprotein (a)-induced biphasic shift in human platelet cyclic AMP. Thromb Res 112(5\u20136):321\u2013324. https:\/\/doi.org\/10.1016\/j.thromres.2004.01.002","journal-title":"Thromb Res"},{"issue":"5","key":"2515_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.thromres.2006.04.013","volume":"119","author":"DE Barre","year":"2007","unstructured":"Barre DE (2007) Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb\/IIIa) receptor. Thromb Res 119(5):601\u2013607. https:\/\/doi.org\/10.1016\/j.thromres.2006.04.013","journal-title":"Thromb Res"},{"issue":"52","key":"2515_CR13","doi-asserted-by":"publisher","first-page":"31151","DOI":"10.1074\/jbc.270.52.31151","volume":"270","author":"C Blencowe","year":"1995","unstructured":"Blencowe C, Hermetter A, Kostner GM, Deigner HP (1995) Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem 270(52):31151\u201331157. https:\/\/doi.org\/10.1074\/jbc.270.52.31151","journal-title":"J Biol Chem"},{"issue":"7","key":"2515_CR14","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1016\/S0021-9258(18)89264-X","volume":"260","author":"LA Miles","year":"1985","unstructured":"Miles LA, Plow EF (1985) Binding and activation of plasminogen on the platelet surface. J Biol Chem 260(7):4303\u20134311","journal-title":"J Biol Chem"},{"issue":"9","key":"2515_CR15","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1161\/01.atv.18.9.1393","volume":"18","author":"ML Rand","year":"1998","unstructured":"Rand ML, Sangrar W, Hancock MA, Taylor DM, Marcovina SM, Packham MA, Koschinsky ML (1998) Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol 18(9):1393\u20131399. https:\/\/doi.org\/10.1161\/01.atv.18.9.1393","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2515_CR16","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cardiores.2004.03.005","volume":"63","author":"LD Tsironis","year":"2004","unstructured":"Tsironis LD, Mitsios JV, Milionis HJ, Elisaf M, Tselepis AD (2004) Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase. Cardiovasc Res 63(1):130\u2013138. https:\/\/doi.org\/10.1016\/j.cardiores.2004.03.005","journal-title":"Cardiovasc Res"},{"key":"2515_CR17","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.1194\/jlr.R800074-JLR200","volume":"50","author":"JA Berliner","year":"2009","unstructured":"Berliner JA, Leitinger N, Tsimikas S (2009) The role of oxidized phospholipids in atherosclerosis. J Lipid Res 50:S207-212. https:\/\/doi.org\/10.1194\/jlr.R800074-JLR200","journal-title":"J Lipid Res"},{"key":"2515_CR18","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2741\/1194","volume":"9","author":"DE Barre","year":"2004","unstructured":"Barre DE (2004) Apoprotein (A) antagonises THE GPIIB\/IIIA receptor on collagen and adp-stimulated human platelets. Front Biosci 9:404\u2013410. https:\/\/doi.org\/10.2741\/1194","journal-title":"Front Biosci"},{"issue":"5","key":"2515_CR19","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1161\/01.atv.16.5.648","volume":"16","author":"A Gries","year":"1996","unstructured":"Gries A, Gries M, Wurm H, Kenner T, Ijsseldijk M, Sixma JJ, Kostner GM (1996) Lipoprotein(a) inhibits collagen-induced aggregation of thrombocytes. Arterioscler Thromb Vasc Biol 16(5):648\u2013655. https:\/\/doi.org\/10.1161\/01.atv.16.5.648","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"17","key":"2515_CR20","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1021\/bi00068a021","volume":"32","author":"A Ezratty","year":"1993","unstructured":"Ezratty A, Simon DI, Loscalzo J (1993) Lipoprotein(a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry 32(17):4628\u20134633. https:\/\/doi.org\/10.1021\/bi00068a021","journal-title":"Biochemistry"},{"issue":"4","key":"2515_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1055\/s-0037-1615654","volume":"85","author":"C Martinez","year":"2001","unstructured":"Martinez C, Rivera J, Loyau S, Corral J, Gonzalez-Conejero R, Lozano ML, Vicente V, Angles-Cano E (2001) Binding of recombinant apolipoprotein(a) to human platelets and effect on platelet aggregation. Thromb Haemost 85(4):686\u2013693","journal-title":"Thromb Haemost"},{"issue":"3","key":"2515_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1161\/01.atv.14.3.345","volume":"14","author":"E Malle","year":"1994","unstructured":"Malle E, Ibovnik A, Stienmetz A, Kostner GM, Sattler W (1994) Identification of glycoprotein IIb as the lipoprotein(a)-binding protein on platelets. Lipoprotein(a) binding is independent of an arginyl-glycyl-aspartate tripeptide located in apolipoprotein(a). Arterioscler Thromb 14(3):345\u2013352. https:\/\/doi.org\/10.1161\/01.atv.14.3.345","journal-title":"Arterioscler Thromb"},{"issue":"9","key":"2515_CR23","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jacc.2006.06.065","volume":"48","author":"W Hochholzer","year":"2006","unstructured":"Hochholzer W et al (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48(9):1742\u20131750. https:\/\/doi.org\/10.1016\/j.jacc.2006.06.065","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"2515_CR24","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1161\/01.Cir.0000160869.75810.98","volume":"111","author":"W Hochholzer","year":"2005","unstructured":"Hochholzer W, Trenk D, Frundi D, Blanke P, Fischer B, Andris K, Bestehorn HP, Buttner HJ, Neumann FJ (2005) Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111(20):2560\u20132564. https:\/\/doi.org\/10.1161\/01.Cir.0000160869.75810.98","journal-title":"Circulation"},{"issue":"3","key":"2515_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.thromres.2006.02.007","volume":"119","author":"W Hochholzer","year":"2007","unstructured":"Hochholzer W, Trenk D, Frundi D, Neumann FJ (2007) Whole blood aggregometry for evaluation of the antiplatelet effects of clopidogrel. Thromb Res 119(3):285\u2013291. https:\/\/doi.org\/10.1016\/j.thromres.2006.02.007","journal-title":"Thromb Res"},{"issue":"12","key":"2515_CR26","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1194\/jlr.P094763","volume":"60","author":"MB Boffa","year":"2019","unstructured":"Boffa MB, Marar TT, Yeang C, Viney NJ, Xia S, Witztum JL, Koschinsky ML, Tsimikas S (2019) Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. J Lipid Res 60(12):2082\u20132089. https:\/\/doi.org\/10.1194\/jlr.P094763","journal-title":"J Lipid Res"},{"issue":"13","key":"2515_CR27","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jacc.2015.01.050","volume":"65","author":"YS Byun","year":"2015","unstructured":"Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S (2015) Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 65(13):1286\u20131295. https:\/\/doi.org\/10.1016\/j.jacc.2015.01.050","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2515_CR28","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1007\/s12325-020-01483-y","volume":"37","author":"R Salsoso","year":"2020","unstructured":"Salsoso R et al (2020) Relation of high lipoprotein (a) concentrations to platelet reactivity in individuals with and without coronary artery disease. Adv Ther 37(11):4568\u20134584. https:\/\/doi.org\/10.1007\/s12325-020-01483-y","journal-title":"Adv Ther"},{"issue":"12","key":"2515_CR29","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML et al (2019) Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation 139(12):1483\u20131492. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037184","journal-title":"Circulation"},{"issue":"2","key":"2515_CR30","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","volume":"75","author":"VA Bittner","year":"2020","unstructured":"Bittner VA et al (2020) Effect of alirocumab on lipoprotein(a) and cardiovascular risk after acute coronary syndrome. J Am Coll Cardiol 75(2):133\u2013144. https:\/\/doi.org\/10.1016\/j.jacc.2019.10.057","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"2515_CR31","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","volume":"41","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Gordts P, Nora C, Yeang C, Witztum JL (2020) Statin therapy increases lipoprotein(a) levels. Eur Heart J 41(24):2275\u20132284. https:\/\/doi.org\/10.1093\/eurheartj\/ehz310","journal-title":"Eur Heart J"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02515-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-021-02515-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-021-02515-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T14:04:51Z","timestamp":1643205891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-021-02515-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2515"],"URL":"https:\/\/doi.org\/10.1007\/s11239-021-02515-2","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"assertion":[{"value":"17 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All other authors report no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}